Efficacy and safety of adjuvant glucocorticoid therapy for Pneumocystis pneumonia (PCP) in patients positive for HIV: a systematic review and meta-analysis
In brief
Glucocorticoids cut death odds by 59% in HIV-positive patients with PCP
In a review of nine articles covering 13 studies, adding glucocorticoids was linked to lower mortality, early deterioration and need for mechanical ventilation among HIV-positive patients with Pneumocystis pneumonia. Reported adverse effects did not differ significantly from control treatment, but the review does not establish which patients benefit most or how results vary across treatment settings.
- Journal
- Frontiers in pharmacology (Q1)
- Published
- 28 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Zhiyong Tang, Rui Li, Xiaoying Chen, Qiang Su, Bin Han, Ming Yang
- PMID
- 43017473
- DOI
- 10.3389/fphar.2026.1916907
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (top studies of the week, 15 November 2026): Meta-analysis evaluates adjunctive treatment for Pneumocystis pneumonia
Abstract
OBJECTIVE: To systematically evaluate the efficacy and safety of glucocorticoids as adjuvant therapy for Pneumocystis pneumonia (PCP) in patients positive for human immunodeficiency virus (HIV). METHODS: Clinical randomized controlled trials or clinical controlled trials evaluating the efficacy and safety of glucocorticoids as adjuvant therapy for PCP in patients who are HIV-positive were retrieved from PubMed, Embase, Web of Science, and the Cochrane Library. Data extraction and methodological quality assessment were performed for eligible studies. Meta-analysis and systematic evaluation were conducted using RevMan v.5.1 and STATA v.12.0 software. RESULTS: Nine articles (13 studies) were included. Compared with the controls, patients treated with glucocorticoids had significantly lower mortality rates (OR = 0.41, 95% CI [0.28-0.59], P < 0.00001), early deterioration rates (OR = 0.08, 95% CI [0.02-0.39], P = 0.002), and lower mechanical ventilation rates (OR = 0.32, 95% CI [0.19-0.55], P < 0.0001). Regarding safety, the incidence of adverse effects did not differ significantly between the two groups (OR = 0.74, 95% CI [0.33-1.70], P = 0.48). CONCLUSION: Adjuvant glucocorticoid therapy significantly reduces mortality, early deterioration, and mechanical ventilation rates in patients who are HIV-positive with PCP without increasing adverse reactions. Glucocorticoids may serve as a viable adjuvant treatment option for PCP in patients who are HIV-positive. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/home, identifier CRD420261418795.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.